1. Scrip
  2. >>Therapy Areas

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

 
• By Mandy Jackson

Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Companies developing new migraine therapies that inhibit calcitonin gene-related peptide (CGRP) or its receptor will test the first-in-class versus best-in-class struggle for market share over the next two years, as late-stage data are reported and applications for drug approvals are submitted.

Amgen Inc., as the only company that's reported Phase III data, is in the lead and plans to submit a biologic license application (BLA) to the US FDA for its erenumab (AMG 334), which targets the CGRP receptor, in the second quarter of this year. Alder BioPharmaceuticals Inc

"Our molecule has a very long half-life, so we can treat quarterly or four times per year rather than monthly

More from Neurological

More from Therapy Areas

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.